IL17A and multiple sclerosis: Targeting IL-17A in mice using vaccines based on IL-17 displayed on Qß or CMVTT has proven efficacious in preclinical models of myocarditis, [75], rheumatoid arthritis and multiple sclerosis [76] as well as psoriasis [77].